Redirecting to https://www.businesswire.com/news/home/20250708931912/en/Avenzo-Therapeutics-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Study-of-AVZO-1418-a-Potential-Best-in-Class-EGFRHER3-Bispecific-Antibody-Drug-Conjugate